73%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
73%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
73%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
73%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
United Therapeutics Corp
Open
SectorHealthcare
482.11 1.14
Overview
Share price change
24h
Min
472.51
Max
485.42
Income | 29M 339M |
|---|---|
Sales | 900K 800M |
P/E Sector Avg | 18.006 84.243 |
Profit margin | 42.364 |
Employees | 1,305 |
EBITDA | 26M 463M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +16.88% upside |
Next Earnings | 25 Feb 2026 |
|---|
Market Cap | 2.7B 21B |
|---|---|
Previous open | 480.97 |
Previous close | 482.11 |
News Sentiment
By Acuity
18%
82%
32 / 352 Healthcare
Technical Score
By Trading Central
Confidence
Weak Bullish Evidence
United Therapeutics Corp Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
United Therapeutics Corp Forecast
Price Target
By TipRanks
16.88% upside
12 Months Forecast
Average 555.2 USD 16.88%
High 645 USD
Low 423 USD
Based on 6 Wall Street analysts offering 12 month price targets forUnited Therapeutics Corp - Dist in the last 3 months.
Sentiment
By Acuity
32 / 352 Healthcare
News Sentiment
Very Strong Bullish Evidence
Volatility
Below average
News Volume (RCV)
Above average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About United Therapeutics Corp
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Live chat